(±)-2-pivalamidopentanoic acid | 1380547-40-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (±)-2-pivalamidopentanoic acid
• 英文别名: N-pivaloylnorvaline；2-Pivalamidopentanoic acid；2-(2,2-dimethylpropanoylamino)pentanoic acid
• CAS: 1380547-40-9
• 化学式: C₁₀H₁₉NO₃
• 分子量: 201.266
• InChiKey: QZQCMSRNYSDKMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Novel high affinity quinoline-based kinase ligands
  申请人：Deng Yongqi

  公开号：US20080045568A1

  公开（公告）日：2008-02-21

  Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

  基于喹啉的细胞周期蛋白依赖激酶2抑制剂，包括这些抑制剂的组合物，以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对治疗疾病或疾病症状有用。该发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法，以及治疗疾病或疾病症状的方法。
• Rebaudioside Analogs
  申请人：PepsiCo, Inc.

  公开号：US20180016291A1

  公开（公告）日：2018-01-18

  The present disclosure provides novel compounds that are steviol derivatives. The compounds generally can be characterized by a structure according to Formula I: wherein A 1 , L 1 , and G 1 are described herein. Also provided are sweetener compositions comprising the compound described herein either as a sweetener or a sweetener enhancer. Additionally, the compound or the sweetener composition can be included in a product such as a beverage product or a food product, which can reduce the amount of sweetener in the product required to achieve the same sweetness level in an otherwise identical product not including the compound or the sweetener composition.

  本公开提供了一些新颖的化合物，这些化合物是史蒂维醇衍生物。这些化合物通常可通过以下式I所示的结构来表征：其中A1、L1和G1如本文所述。还提供了包含所述化合物的甜味剂组合物，可以作为甜味剂或增甜剂。此外，该化合物或甜味剂组合物可以包含在产品中，例如饮料产品或食品产品中，可以减少产品中所需的甜味剂量，以达到在另一种不包含该化合物或甜味剂组合物的相同产品中所需的甜度水平。
• DUAL-ACTING ANTIHYPERTENSIVE AGENTS
  申请人：CHOI Seok-Ki

  公开号：US20120129900A1

  公开（公告）日：2012-05-24

  The invention is directed to compounds of formula I: wherein Ar, r, R 3 , X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.

  本发明涉及化合物I的公式：其中Ar、r、R3、X和R5-7如说明书所定义的，以及其药学上可接受的盐。公式I的化合物具有AT1受体拮抗活性和脑利钠肽酶抑制活性。本发明还涉及包含这种化合物的制药组合物；使用这种化合物的方法；以及制备这种化合物的过程和中间体。
• US7511063B2
  申请人：——

  公开号：US7511063B2

  公开（公告）日：2009-03-31
• US8394846B2
  申请人：——

  公开号：US8394846B2

  公开（公告）日：2013-03-12